[Valorisation of high technology radiotherapy in Europe].
In order to support adoption and dissemination into clinical practice of innovative treatment strategies, being almost by definition more expensive than the corresponding standard treatments, an appropriate reimbursement is a prerequisite. This article describes different possible financing systems in the context of technological advances in radiation oncology and analyses if and how the reimbursement issue has been tackled in European radiotherapy centres.
Lievens
Y
Y
Département de Radiothérapie Oncologique, Universitaire Ziekenhuizen Leuven, Herestraat 49, 3000 Leuven, Belgique. yolande.lievens@uz.kuleuven.ac.be
D001530:Belgium; D003365:Costs and Cost Analysis; D005060:Europe; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D011878:Radiotherapy / Q000191:economics / Q000379:methods* / Q000639:trends; D012051:Reimbursement Mechanisms; D015203:Reproducibility of Results; D013672:Technology / Q000191:economics / Q000639:trends*